Current clinical challenges in lipid control include achieving and maintaining target LDL-cholesterol levels in patients at high risk for atherosclerotic cardiovascular disease, especially those who do not respond adequately to standard therapies. The VICTORION-Difference trial demonstrated that an inclisiran-based treatment strategy significantly outperformed usual care in helping patients reach early and sustained LDL-C goals. This approach also resulted in fewer muscle-related side effects, a common barrier to adherence. Inclisiran offers a convenient, effective, and well-tolerated option for improving lipid management in these patients.
In this interview, Drs. Kim A. Williams and Ulf Landmesser discuss "VICTORION-Difference: Inclisiran-Based Strategy vs. Standard of Care."
Subscribe to ACCEL
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research